0
Abstract: Slide Presentations |

CATEGORICAL DECLINES IN PERCENT PREDICTED FORCED VITAL CAPACITY (PP-FVC) ARE ASSOCIATED WITH A GRADED RISK OF DEATH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) FREE TO VIEW

Roland M. du Bois, MD*; Carlo Albera, MD; Ulrich Costabel, MD; Paul W. Noble, MD; Javier Szwarcberg, MD; Michiel Thomeer, MD; Dominique Valeyre, MD; Derek Weycker, PhD; Talmadge E. King, Jr., MD
Author and Funding Information

Royal Brompton Hospital, London, United Kingdom


Chest


Chest. 2008;134(4_MeetingAbstracts):s20003. doi:10.1378/chest.134.4_MeetingAbstracts.s20003
Text Size: A A A
Published online

Abstract

PURPOSE:IPF is a fatal lung disease of unknown etiology for which there is no proven therapy. While several studies have reported that a decline of ≥10% in FVC at 6 or 12 months is associated with an increased risk of death, recent data suggest that a minority of patients experience a change of this magnitude over these time intervals. In the present study, we examined the relationship between categorical changes in PP-FVC and the risk for all cause mortality in patients with IPF.

METHODS:We assessed the relationship between change in PP-FVC and subsequent mortality using pooled data from 443 patients in the placebo arms of 2 randomized trials in patients with IPF. Data collected at serial 24-week study visits were employed in the analyses. Absolute change in PP-FVC, the difference between the end and the beginning of a 24-week period, was stratified based on quintiles of observed deaths assessed over the following 24-week period. Analyses were exploratory and unadjusted for potential confounders. Results are expressed as percentages along with corresponding 95% confidence intervals.

RESULTS:A total of 63 deaths were observed. Of these, 17 (4% of patients) occurred during the first 24 weeks and were therefore excluded from the analysis. Categorical declines in PP-FVC during the preceding 24 weeks were associated with a graded increased risk of death during the subsequent 24 weeks. Mortality (95% CI) associated with a categorical change in absolute PP-FVC of >0, >-4 to ≤;0, >-8 to ≤;-4, >-18 to ≤;-8, and ≤;-18; was 1.7% (0.8–3.4), 2.1% (1.1–3.9), 3.3% (1.7–6.4), 7.6% (4.0–13.8), and 41.7% (24.5–64.2), respectively.

CONCLUSION:These findings suggest that in patients with IPF, categorical declines in PP-FVC at 24 weeks are associated with a graded risk of death in the following 24-week period. Additional analyses using multivariate models incorporating relevant covariates are being undertaken.

CLINICAL IMPLICATIONS:These preliminary data highlight the prognostic value of categorical changes in FVC for predicting mortality in IPF patients.

DISCLOSURE:Roland du Bois, Employee Dr. Szwarcberg is an employee of InterMune.; Consultant fee, speaker bureau, advisory committee, etc. Dr. du Bois is a consultant to Actelion, Boehringer Ingelheim, Genzyme, and InterMune; Dr. Albera is a consultant to InterMune; Dr. Costabel is a consultant to InterMune; Dr. Noble is a consultant and advisory committee member to InterMune; Dr. Thomeer is a consultant to InterMune; Dr. Valeyre is a consultant to InterMune; Dr. Weycker is a consultant to InterMune; Dr. King is a consultant and advisory committee member to Actelion, ImmuneWorks, and InterMune. Dr. King is also a consultant to AstraZeneca, Genzyme, Gilead, GlaxoSmithKline, and Merck.; Other This study was sponsored by InterMune.; No Product/Research Disclosure Information

Monday, October 27, 2008

2:30 PM - 4:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543